300401 Stock Overview
Zhejiang Garden Biopharmaceutical Co.,Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Zhejiang Garden Biopharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.80 |
| 52 Week High | CN¥18.46 |
| 52 Week Low | CN¥7.58 |
| Beta | 0.085 |
| 1 Month Change | -4.96% |
| 3 Month Change | -7.44% |
| 1 Year Change | 61.97% |
| 3 Year Change | 4.86% |
| 5 Year Change | 16.65% |
| Change since IPO | 583.85% |
Recent News & Updates
Fewer Investors Than Expected Jumping On Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401)
Jan 06
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues
Oct 24Recent updates
Fewer Investors Than Expected Jumping On Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401)
Jan 06Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues
Oct 24Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Sep 29Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Sep 08Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge
Jun 30Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?
May 31Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%
May 06Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 22Shareholder Returns
| 300401 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.6% | 0.2% | -0.9% |
| 1Y | 62.0% | 12.8% | 22.0% |
Return vs Industry: 300401 exceeded the CN Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: 300401 exceeded the CN Market which returned 22% over the past year.
Price Volatility
| 300401 volatility | |
|---|---|
| 300401 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 300401 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300401's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 943 | Huanzheng Ma | www.hybiotech.com |
Zhejiang Garden Biopharmaceutical Co.,Ltd. manufactures and supplies lanolin cholesterol, vitamin D3, 25-hydroxyvitamin D3, and refined lanolin products in China. It offers cholesterol; feed grade cholesterol; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3.
Zhejiang Garden Biopharmaceutical Co.,Ltd. Fundamentals Summary
| 300401 fundamental statistics | |
|---|---|
| Market cap | CN¥7.50b |
| Earnings (TTM) | CN¥284.89m |
| Revenue (TTM) | CN¥1.13b |
26.3x
P/E Ratio6.6x
P/S RatioIs 300401 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300401 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.13b |
| Cost of Revenue | CN¥473.20m |
| Gross Profit | CN¥661.26m |
| Other Expenses | CN¥376.38m |
| Earnings | CN¥284.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 25, 2025
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 58.29% |
| Net Profit Margin | 25.11% |
| Debt/Equity Ratio | 55.6% |
How did 300401 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield13%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 05:18 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Garden Biopharmaceutical Co.,Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhe Wang | Citic Securities Co., Ltd. |
| Wei Liu | Haitong International Research Limited |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |